Meu SciELO
Serviços Personalizados
Journal
Artigo
Indicadores
- Citado por SciELO
- Acessos
Links relacionados
- Citado por Google
- Similares em SciELO
- Similares em Google
Compartilhar
Revista de la Sociedad Española del Dolor
versão impressa ISSN 1134-8046
Resumo
PEREZ-CAJARAVILLE, J. e GIL-ALDEA, I.. New perspectives in the treatment of neuropathic pain: duloxetine. Rev. Soc. Esp. Dolor [online]. 2006, vol.13, n.6, pp.421-427. ISSN 1134-8046.
Duloxetine is a novel antidepressant agent reuptake inhibitor of serotonin and norepinephrine, with good perspective in the treatment of neuropathic pain. Orally administered duloxetine is well absorbed. Elimination of duloxetine is mainly through hepatic metabolism involving two CYP450 isozymes, CYP1A2 and CYP2D6. Duloxetine may cause some adverse events: nausea, dry mouth or constipation. Normally are mild to moderate and they disappear when the treatment continues. Duloxetine is used for treatment of major depressive disorder and diabetic peripheral neuropathic pain. Recently it has also been approved for treatment of stress urinary incontinence moderate to severe in women. It has also being studied in several clinical trials for the treatment of other kind of pathology, including fibromyalgia.
Palavras-chave : Duloxetine; treatment; neurophatic pain; mayor depressive disorder; stress urinary incontinence; fibromyalgia.